
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update
Current Role of Blood Tests for Colorectal Cancer Screening</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}
/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}
/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}
.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}
.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}
/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 25px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}
/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}
/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}
/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}
/* Custom arrow icon */
.mindmap summary::before {
    content: "â–¶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}
/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}
/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}
.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}
/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}
/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}
/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}
/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}
/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}
/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}
/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}
/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}
/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}
/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}
.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}
/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}
/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */
/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}
.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}
/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}
</style>

</style>
</head>
<body>
<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>
<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>AGA Clinical Practice Update</strong><br><em>Current Role of Blood Tests for Colorectal Cancer Screening</em></summary>
            <div>
                <ul><li>Journal: Clinical Gastroenterology and Hepatology</li><li>Volume: 23, Issue 9</li><li>Publication Date: August 2025</li><li>Commentary on the evidence and implications of blood tests for CRC screening.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What is the sensitivity of the Guardant Shield test for <b>Stage 1</b> CRC?</li><li>2. For a triennial blood test to approximate the benefits of annual FIT, what is the required <b>Advanced Precursor Lesion (APL)</b> sensitivity?</li><li>3. What percentage of patients fail to complete a timely colonoscopy (within 3-6 months) after a positive stool-based test?</li><li>4. Modeling suggests population outcomes would be similar if for every 3 people who substituted a blood test for a current test, how many <b>new</b> screenees were added?</li><li>5. What is the CMS-approved screening interval for the Guardant Shield blood test?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Background & Rationale</strong></summary>
            <div>
                <ul><li><b>Colorectal Cancer (CRC)</b> is the <u>3rd most common cancer</u> and <u>2nd leading cause of cancer death</u> in the US.</li><li>Screening is the most effective strategy to reduce CRC burden but remains underutilized.</li><li>Advances in technology now allow detection of circulating tumor DNA (ctDNA) or cell-free DNA (cfDNA) in blood, leading to new screening tests.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Novel Blood Tests: Performance & Status</strong></summary>
            <div>
                <ul><li>Two main tests have reported results from population-based clinical validation studies.</li></ul>
                
        <details>
            <summary><strong>Guardant <b>Shield</b> Test</strong></summary>
            <div>
                <ul><li>Mechanism: Detects <u>cell-free DNA</u> in blood.</li><li>Status: <b>FDA approved</b> (May 2024), <b>CMS approved</b>, and commercially available.</li><li>Recommended Interval: Every <q><b>3 years</b></q> per CMS.</li></ul>
                
        <details>
            <summary><strong>Performance Characteristics</strong></summary>
            <div>
                <ul><li>Overall CRC Sensitivity: <q><b>83.1%</b></q></li><li>Overall CRC Specificity: <q><b>89.6%</b></q></li><li>Advanced Precursor Lesion (APL) Sensitivity: <q><u><b>13.2%</b></u></q></li><li>Stage 1 CRC Sensitivity: <q><u><b>55%</b></u></q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Freenome</b> Test</strong></summary>
            <div>
                <ul><li>Mechanism: Detects <u>methylation markers</u> from cell-free DNA.</li><li>Status: Expected to seek FDA and CMS approvals.</li></ul>
                
        <details>
            <summary><strong>Performance Characteristics</strong></summary>
            <div>
                <ul><li>Overall CRC Sensitivity: <q><b>79.2%</b></q></li><li>Overall CRC Specificity: <q><b>91.5%</b></q></li><li>Advanced Precursor Lesion (APL) Sensitivity: <q><u><b>12.5%</b></u></q></li><li>Stage 1 CRC Sensitivity: <q><u><b>57.1%</b></u></q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Comparative Test Performance (See Table 1)</strong></summary>
            <div>
                <ul><li>A summary of diagnostic performance of blood tests compared to established stool tests and colonoscopy.</li></ul>
                
        <details>
            <summary><strong><b>Colonoscopy</b> (Every 10y)</strong></summary>
            <div>
                <ul><li>CRC Sensitivity: <q>96%</q></li><li>APL Sensitivity: <q>95%</q></li><li>Specificity: <q>90%</q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>FIT</b> (Annual)</strong></summary>
            <div>
                <ul><li>CRC Sensitivity: <q>74%</q></li><li>APL Sensitivity: <q>24%</q></li><li>Specificity: <q>96%</q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>MT-sDNA</b> (Cologuard, Every 3y)</strong></summary>
            <div>
                <ul><li>CRC Sensitivity: <q>92%</q></li><li>APL Sensitivity: <q>42%</q></li><li>Specificity: <q>87%</q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><u>Blood Tests</u> (Shield & Freenome)</strong></summary>
            <div>
                <ul><li>CRC Sensitivity: <q>~79-83%</q></li><li>APL Sensitivity: <q><b>~13%</b></q> (critically low)</li><li>Specificity: <q>~90-92%</q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Implications & Limitations of Blood Tests</strong></summary>
            <div>
                <ul><li>The performance characteristics of current blood tests have significant clinical consequences.</li></ul>
                
        <details>
            <summary><strong><u>Reduced Prevention & Early Detection</u></strong></summary>
            <div>
                <ul><li><b>Poor APL detection</b> (<q>~13%</q>) severely limits the potential for <u>cancer prevention</u>.</li><li><b>Suboptimal early-stage CRC detection</b> (<q>~55-57%</q> for Stage 1) reduces the chance for <u>curative treatment</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Potential for Improved Adherence</strong></summary>
            <div>
                <ul><li>A key attraction is bringing currently unscreened individuals into screening programs.</li><li>One RCT showed adherence up to <q><b>11%</b></q> higher for blood testing compared to stool testing.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Unknown Optimal Interval</strong></summary>
            <div>
                <ul><li>Published data is for one-time test performance.</li><li>The optimal repeat interval is currently unknown.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Modeling Studies: Projected Long-Term Outcomes</strong></summary>
            <div>
                <ul><li>Decision analytic models project long-term benefits and costs, as large-scale RCTs are not feasible.</li></ul>
                
        <details>
            <summary><strong>Projected Risk Reduction vs. No Screening (See Table 2)</strong></summary>
            <div>
                <ul><li>Models consistently show blood tests are <u>substantially less effective</u> than established screening methods.</li></ul>
                
        <details>
            <summary><strong><b>Established Tests</b> (FIT, MT-sDNA, Colonoscopy)</strong></summary>
            <div>
                <ul><li>CRC Incidence Reduction: <q>40% - 81%</q></li><li>CRC Mortality Reduction: <q>64% - 88%</q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Triennial Guardant Shield</b></strong></summary>
            <div>
                <ul><li>CRC Incidence Reduction: <q><u><b>24% - 47%</b></u></q></li><li>CRC Mortality Reduction: <q><u><b>53% - 59%</b></u></q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Cost-Effectiveness Analysis</strong></summary>
            <div>
                <ul><li>At its list price of <q><b>$1450</b></q>, Guardant Shield is considered <u>prohibitively costly</u> versus alternatives.</li><li>It is cost-effective compared to <u>no screening</u>.</li><li>At a hypothetical cost of <q>$300</q>, it would still be less effective and more costly than FIT or colonoscopy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hypothetical Improvements Needed</strong></summary>
            <div>
                <ul><li>For a triennial blood test to approximate the benefits of <b>annual FIT</b>, it would require:</li><li>APL Sensitivity ---> <q><b>50% - 80%</b></q> (current is ~13%).</li><li>Cost ---> <q><b><$125 - $140</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Utilization & Programmatic Challenges</strong></summary>
            <div>
                <ul><li>A test's real-world effectiveness depends on both its efficacy and its uptake.</li></ul>
                
        <details>
            <summary><strong>The <b>Substitution Problem</b></strong></summary>
            <div>
                <ul><li>A major concern is that patients will <u>substitute</u> a less effective blood test for more effective options (FIT, colonoscopy), leading to <u>inferior population outcomes</u>.</li><li>To be as effective as FIT/colonoscopy, blood test participation would need to be <q><b>at least 35% higher</b></q>.</li><li>Population outcomes would be similar if for every <q>3 people</q> who substitute, <q><b>2 new people</b></q> are screened.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Programmatic Requirements</strong></summary>
            <div>
                <ul><li>Like all non-invasive tests, blood tests require a programmatic approach.</li><li><b>Positive Test</b> ---> Must complete a follow-up <u>colonoscopy</u>.</li><li><b>Negative Test</b> ---> Must have repeat testing at the recommended interval.</li></ul>
                
        <details>
            <summary><strong>Challenge: Follow-up Colonoscopy</strong></summary>
            <div>
                <ul><li>Data from stool-based tests shows that <q>almost 50%</q> of patients do not complete a timely colonoscopy (within 3-6 months) after a positive result.</li><li>Delayed colonoscopy leads to higher CRC incidence and mortality.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Disparities in Screening</strong></summary>
            <div>
                <ul><li>It is unknown if blood tests will worsen or lessen disparities.</li><li>Screening rates are lowest in Hispanics (<q>~50%</q>).</li><li>Barriers like access to a lab for a blood draw may be more challenging than mailing a stool kit for some populations (e.g., rural).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Multicancer Detection (MCD) Tests</strong></summary>
            <div>
                <ul><li>These tests aim to detect multiple cancers, including CRC, from a single blood draw.</li></ul>
                
        <details>
            <summary><strong>Example: <b>Galleri Test</b> (Grail)</strong></summary>
            <div>
                <ul><li>Early validation study showed:</li><li>Overall Cancer Sensitivity: <q><b>51.5%</b></q></li><li>Specificity: <q><b>99.5%</b></q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Challenges & Concerns</strong></summary>
            <div>
                <ul><li>Imperfect confirmatory imaging tests.</li><li>Substantial cost and resources for workup of a positive signal.</li><li>Unclear if screening for many cancers this way reduces mortality (risk of lead/length time bias).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Conclusions & Key Takeaways</strong></summary>
            <div>
                <ul><li>Final recommendations on the current role of blood tests in CRC screening.</li></ul>
                
        <details>
            <summary><strong><u>Primary Recommendation</u></strong></summary>
            <div>
                <ul><li>The first available CRC screening blood tests are best viewed as an <b>acceptable option</b> only in persons who <u>decline all established forms of CRC screening</u> (FIT, MT-sDNA, colonoscopy).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Patient Counseling Points</strong></summary>
            <div>
                <ul><li>Patients must understand that a <b>positive blood test</b> requires a <u>follow-up colonoscopy</u>.</li><li>Patients should be informed that current blood tests result in <b>lower prevention rates</b> for CRC and CRC death compared to programmatic FIT, Cologuard, or colonoscopy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Potential for Net Harm</strong></summary>
            <div>
                <ul><li>Use of novel blood tests could result in <b>net harm</b> if they are <u>substituted</u> for more effective screening tests by patients who would have otherwise completed an established test.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>
<br>
<br>
<br>
<br>
<br>

<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;
// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}
// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}
function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}
function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}
// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}
// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}
// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);
    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }
    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
